A recent systematic review ranked the relative strength of evidence supporting different PAH-related mutations, and listed several mutations in the TGF-β signaling pathway in addition to BMPR2 which were classified as having definitive, moderate, limited and disputed evidence for being causal in PAH [3]. This evidence concerns the gene BMPR2 and pulmonary arterial hypertension.